PDGF-DD Ligand Activates NKp44 Receptors for Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies lack effective mechanisms to activate Natural Killer (NK) cells and innate lymphoid cells (ILCs) for cancer treatment, infectious disease management, and autoimmune disorder control, as the physiological ligands for many germ line-encoded receptors on these cells remain elusive.
Innovation Solution
Identification of PDGF-DD as a ligand for NKp44, which activates NK cells and ILCs, leading to cytokine secretion and immune modulation, with compositions and methods utilizing PDGF-DD to stimulate NKp44-expressing cells for enhanced anti-tumoral activity, vaccine responses, and regulation of autoimmune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapies are used, then treatment is provided, but effective activation of NK cells and ILCs is not achieved due to elusive physiological ligands
Solution Approach 1:
The patent uses PDGF-DD as an intermediary molecule that bridges the gap between available therapeutic agents and NK cell activation. PDGF-DD serves as a soluble ligand that can be administered systemically to activate NKp44 receptors on NK cells and ILCs, thereby mediating the immune activation effect without requiring direct cell-to-cell contact or complex engineered receptors
Solution Approach 2:
The patent leverages the endogenous PDGF-DD ligand that is already present in the body and can be utilized by the immune system. By administering recombinant PDGF-DD or stimulating endogenous production, the body's own immune cells are activated through their natural receptor-ligand interaction, eliminating the need for complex external activation mechanisms
2Adaptability or versatility
If germ line-encoded receptors are used without identified ligands, then immune recognition capability is maintained, but functional activation cannot be achieved
Solution Approach 1:
PDGF-DD acts as a mediator that connects the NKp44 receptor to functional activation. The soluble ligand can be administered systemically and will naturally bind to NKp44 on activated NK cells and ILCs, providing a simple method to activate these cells without requiring complex engineering of the receptors themselves
Solution Approach 2:
The patent changes the activation parameter from requiring complex receptor engineering to simply administering a soluble ligand (PDGF-DD). This parameter change simplifies the activation process from a complex cellular engineering task to a straightforward pharmacological intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PDGF-DD stimulation of NKp44-expressing cells induces cytokine secretion, including IFN-γ and TNF-α, mediating tumor growth arrest and enhancing immune responses, offering a novel mechanism for cancer therapy and autoimmune disorder management.
Implementation Method 1
PDGF-DD is a ligand for NKp44, which activates NK cells and ILCs
Implementation Method 2
These receptors transmit activating intracellular signals by recruiting the protein tyrosine kinases Syk or ZAP70, either directly or through the adaptors DAP12 and FcRγ. These immunoreceptor tyrosine-based activation motif (ITAM) signaling pathways are similar to those induced by antigen-specific receptors.
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of methods and compositions for modulating the Natural Cyotoxicity Receptor 2 (NCR2).